Navigation Links
Ben-Gurion U. and Sorrento Therapeutics sign agreement to develop anti-hepatitis C virus antibodies
Date:7/9/2013

SAN DIEGO AND BEER-SHEVA, ISRAELJuly 9, 2013 -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and B.G. Negev Technologies and Applications Ltd., the technology transfer company of Ben-Gurion University of the Negev (BGU), have announced an option and license agreement to develop therapeutic products to treat Hepatitis C Virus (HCV).

"We are pleased to be collaborating with Sorrento to develop our fully human anti-HCV antibody clones into potential anti-HCV therapeutics," said Leslie Lobel, M.D., Ph.D., a lecturer and vice chair of the Department of Microbiology, Immunology and Genetics in BGU's Faculty of Health Sciences. Dr. Lobel identified the antibody clones from patients who have recovered from HCV infections.

According to the Centers for Disease Control (CDC), more than 170 million people worldwide are chronically infected with Hepatitis C Virus (HCV), including approximately 3.2 million people in the United States.

This collaborative effort utilizes the respective strengths of each organization to create an important product opportunity consisting of therapeutic and/or prophylactic agents against HCV infections. Sorrento, a San Diego-based company, will be responsible for developing the anti-HCV antibody products.

"Sorrento has already achieved many successes using its proprietary G-MAB library to identify, characterize and develop fully human antibodies against difficult targets relevant to infectious agents," said Henry Ji, Ph.D., president and chief executive officer of Sorrento.

"We are excited to be working with Dr. Lobel to add a program targeting HCV to our existing portfolio of therapeutic antibodies for the prevention and/or treatment of major infectious diseases." Doron Krakow, executive vice president of American Associates, Ben-Gurion University of the Negev said, "It is exciting that another medical breakthrough emanating from BGU's research laboratories will potentially become a product that could help people suffering from hepatitis.

"Dr. Lobel was a pioneer at BGU, born and educated in the U.S., who chose to establish his research in the Negev Desert rather than at a top American medical university, so this is a truly significant development," Krakow added.


'/>"/>

Contact: Andrew Lavin
andrewlavin@alavin.com
516-944-4486
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Related medicine news :

1. Ben-Gurion U. and Cincinnati Childrens Hospital to develop pediatric-specific medical technologies
2. Ben-Gurion U. researchers successfully test solar desalination system for arid land agriculture
3. Viewing terrorist attacks on TV increases pain intensity -- Ben-Gurion U. researchers
4. New Facebook app to detect pedophiles and criminals developed by Ben-Gurion U. researchers
5. Lauren Sciences LLCs research team at Ben-Gurion University awarded Campbell Foundation grant to develop a V-Smart therapeutic for neuro-HIV
6. Non-invasive treatment for children with obstructive sleep apnea suggested by Ben-Gurion University study
7. Ben-Gurion U and Cincinnati Childrens Hospital to develop new pediatric medical devices
8. Israel rocket attacks increase miscarriage likelihood -- Ben-Gurion U. research study
9. Targeted therapeutics for colon cancer to be presented at AACR meeting
10. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
11. FORMA Therapeutics teams with TGen Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Donna Bergman, professor of ... and published an article in the medical science journal Physical Medicine and Rehabilitation ... article and the research that helped produce it, were written and conducted in ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... Winner for its Product Innovation in the prestigious CEO World Awards®. The coveted ... performance, new products and services, CEO case studies, corporate social responsibility, and milestones ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Cheerag D. ... Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health ... 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon Goodwill Industries, ... opportunity that helps high school girls succeed in STEM programs as well as ... Goodwill will host over 20 high school girls at their corporate headquarters on ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Every year, thousands ... and educational conference, InstructureCon. Each annual event is coupled with a dynamic theme like ... a James Bond theme, Mission: InstructureCon 0017. , To extend their partnership with ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of ... their families to thrive on nutrition support. To celebrate its ... new site has a fresh new look with improved organization to create ... ... ...
(Date:7/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... pharmaceutical company focused on the development of oral drug delivery ... Israel Securities Authority to dual-list its common stock on the ... trading on the TASE on July 12, 2017 under the ... Company, it is expected that Oramed will be included in ...
(Date:7/5/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic ... today announced that it has reached an agreement with ... shareholder, to modify its existing credit facility effective June ... WAVI agreed to exchange its existing $4.25 million credit ...
Breaking Medicine Technology: